HCT/HGB on TRT: When to Worry and What to Do

TRT stimulates red blood cell production. More red blood cells can improve oxygen delivery and energy—but too many thicken your blood, increasing cardiovascular risk. Here's how to manage hematocrit and hemoglobin safely.

What Are Hematocrit and Hemoglobin?

Hematocrit (HCT)

The percentage of your blood that is red blood cells. Think of it as blood "thickness."

• Normal range: 38-50%
• On TRT target: Under 52%
• Concerning: Above 54%

Hemoglobin (HGB)

The protein in red blood cells that carries oxygen.

• Normal range: 13.5-17.5 g/dL
• On TRT target: Under 18 g/dL
• Concerning: Above 19 g/dL

Why TRT Raises HCT/HGB

Testosterone stimulates erythropoiesis—the production of red blood cells. This is actually a benefit (more oxygen capacity, better energy), but it can go too far.

Higher testosterone doses and larger infrequent injections tend to raise HCT more than lower doses or frequent smaller injections.

Why High HCT/HGB Matters

Thick blood doesn't flow as easily. Risks include:

• High blood pressure: Heart works harder to pump thick blood
• Blood clots: Increased risk of stroke, heart attack, DVT
• Headaches: From increased blood viscosity
• Fatigue: Paradoxically, very high HCT can cause tiredness

How to Test

Baseline

Get HCT/HGB tested before starting TRT. Know your starting point.

Follow-Up Schedule

• 3 months: First check after starting TRT
• 6 months: Second check
• Every 6 months: Once stable
• Immediately: If you have symptoms (headaches, high BP)

Test Correctly

Dehydration artificially elevates HCT. Always test well-hydrated:

• Drink water the day before and morning of the test
• Avoid intense exercise 24 hours prior
• Don't test after sauna or hot tub

Management Strategies

Level 1: Hydration (HCT 50-52%)

If HCT is slightly elevated:

• Increase water intake to 80-100 oz daily
• Retest in 2-4 weeks
• Many "high" readings are actually dehydration

Level 2: Therapeutic Phlebotomy (HCT 52-54%)

Donate blood or have your doctor draw and discard blood.

• One unit (about 500mL) typically drops HCT by 2-3%
• Schedule at blood bank or doctor's office
• Don't donate more than every 8 weeks
• Track ferritin (iron stores)—frequent donation depletes it

Level 3: Dose Adjustment (HCT Consistently Above 54%)

If HCT stays high despite donations, you may need less testosterone.

• Reduce weekly dose by 20-30%
• Try more frequent injections (daily or EOD instead of weekly)
• Retest HCT in 6-8 weeks

Monitoring Iron (Ferritin)

Frequent blood donation depletes iron stores. Low ferritin causes:

• Fatigue
• Weakness
• Poor exercise performance
• Compromised immune function

Check Ferritin If:

• Donating blood more than 3 times per year
• Feeling tired despite good testosterone levels

Target Ferritin:

• 50-150 ng/mL
• Supplement with iron if below 30

Lifestyle Factors

What Raises HCT (Avoid)

• Dehydration: Most common cause of false elevation
• High altitude: Living/training at elevation raises HCT naturally
• Sleep apnea: Untreated apnea elevates HCT
• Smoking: Raises HCT and cardiovascular risk

What Helps Lower HCT

• Hydration: Stay well-hydrated always
• Grapefruit: Some evidence it slightly lowers HCT (check med interactions)
• Cardiovascular exercise: Improves circulation

When to Lower TRT Dose

Consider dose reduction if:

• HCT consistently above 54% despite donations
• Needing to donate more than 4 times per year
• Experiencing headaches or high blood pressure
• Ferritin depleted from frequent donations

Remember: The goal is optimal health, not maximum testosterone levels. A lower dose with normal HCT is better than a higher dose with thick blood.

Key Takeaways

• Test HCT/HGB every 3-6 months on TRT
• Stay well-hydrated before testing
• Target HCT under 52%, HGB under 18 g/dL
• Donate blood when HCT exceeds 52-54%
• Don't donate more than every 8 weeks
• Monitor ferritin if donating frequently
• Reduce TRT dose if HCT stays high despite management

Want the full picture? Read the complete TRT lab guide covering all markers.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. Link
2. Cervi A, Balitsky AK. Testosterone therapy and secondary erythrocytosis. Can Urol Assoc J. 2022;16(5):E245-E248. Link
3. Ohlander SJ, Varghese B, Ghai R, Tran LN, Lundy SD. Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male. Sex Med Rev. 2018;6(1):77-85. Link
4. Soria-Gondek A, Whisenant SJ, Engoren M, et al. Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism. J Urol. 2022;207(5):1046-1054. Link
5. Madden JM, O'Malley KJ. Management of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide. Mayo Clin Proc. 2022;97(11):2128-2137. Link
6. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. Link